Davide Gianni, PhD

AstraZeneca, England, United Kingdom

Davide Gianni got his PhD at the University of Naples "Federico II" and continued his postdoctoral studies at The Scripps Research Institute in San Diego California. He moved into industry in 2010 when he joined Boehringer-Ingelheim as a Research Laboratory Head in Vienna to lead a team of scientists to identify and validate novel targets for cancer therapies. In 2015 he moved to AstraZeneca in Cambridge UK where he has been leading the Functional Genomics team aimed at applying numerous perturbation modalities (including CRISPR/Cas9) to identify novel target opportunities for therapy areas of interest for AZ.. In his career he has authored >20 publications aimed at uncovering molecular mechanisms underpinning human diseases. He brings expertise in the field of target identification and validation as well as human genetics and molecular biology.

Disclosure information not submitted.

Presentation(s):

• Use of Genetic and Non-Genetic Agents for Target Validation

  Sunday, February 4, 2024
  1:00 PM – 4:30 PM EST

• Panel Discussion | Functional genomics for target identification: What has been achieved, what are the current challenges and what are the future opportunities

  Tuesday, February 6, 2024
  8:30 AM – 10:00 AM EST